Our Team

Ricardo N. Ramirez, is a genome and data science leader with deep expertise in epigenetics, computational biology, immunology, and gene-editing technologies, bringing together discovery science and translational strategy to advance precision therapies for rare disease.

He earned his PhD at the University of California, Irvine, where he integrated epigenomic profiling and computational modeling to map gene-regulatory networks governing human myeloid differentiation, contributing to both the ENCODE and STATegra consortia. He then completed a postdoctoral fellowship at Harvard Medical School, focusing on adaptive immunity and regulatory T cells, where he demonstrated how 3D chromatin architecture controls lineage-specific gene expression through the master regulator FoxP3 as part of the ImmGen consortium.

Ricardo later joined a Boston-based biotech company as Data Science Lead, directing genomic specificity and safety strategies for next-generation epigenetic medicines advancing toward the clinic. This work placed him at the intersection of discovery biology, regulatory science, and therapeutic development.

He is the founder of a data science consulting practice RNR Consulting LLC, that partners with biotech companies and nonprofit foundations to drive drug discovery, computational modeling, and multi-omic data integration. Through his early collaboration with COMBINEDBrain, Ricardo recognized the power of patient-driven science in accelerating cures for rare disorders.

As Chief Scientific Officer for the MED13L Foundation, Ricardo leads investigational research and preclinical strategy to advance viable therapies for those affected by MED13L syndrome. With a deep value to providing effective leadership, he is equally committed to serving families—bridging science, lived experience, and advocacy to unite researchers, clinicians, and caregivers. By centering family voices alongside scientific rigor, Ricardo helps ensure that research efforts remain aligned with real-world needs and focused on delivering meaningful impact for the MED13L community.